 2. Patients who have been treated with most recent radiotherapy, hormonal therapy, immunotherapy, chemotherapy or investigational drugs within 21 days or 5 half-lives whichever is shorter from enrolment screening, andor who have any unresolved NCI Common Terminology Criteria of Adverse Events CTCAE v4.03 Grade 1 treatment-related side effect with the exception of alopecia. 